Quest Diagnostics’ study confirms accuracy of blood tests for Alzheimer’s disease diagnosis

Quest Diagnostics’ blood-based test panels demonstrate confirmatory accuracy, potentially reducing the need for PET imaging

BMS unveils new data highlighting sustained efficacy and safety of Sotyktu in psoriatic arthritis and lupus

Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions

Biocon Biologics secures Health Canada nod for biosimilars Yesintek, Yesintek IV

Yesintek and Yesintek I.V. are approved for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients

Merck breaks ground on $3 billion center of excellence for pharma manufacturing in Virginia

The expansion underscores Merck’s commitment to invest more than $70 billion in U.S. research, development and capital projects

Roche presents positive phase III data for vamikibart in uveitic macular edema

Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME

FDA approves Tezspire for chronic rhinosinusitis with nasal polyps

Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation

Cupid achieves CE (EU IVDR) certification for pregnancy and syphilis test kits

Biocon Biologics and Civica launch private-label Insulin glargine

Roche’s Elecsys pTau181 becomes first FDA-cleared blood test to rule out Alzheimer’s pathology in primary care

New test expands access to early Alzheimer’s assessment, streamlining diagnostic pathways and improving referral efficiency

Relmada therapeutics appoints Dr. Max Kates to propel NDV-01 toward phase 3

Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026